<code id='135734A5A7'></code><style id='135734A5A7'></style>
    • <acronym id='135734A5A7'></acronym>
      <center id='135734A5A7'><center id='135734A5A7'><tfoot id='135734A5A7'></tfoot></center><abbr id='135734A5A7'><dir id='135734A5A7'><tfoot id='135734A5A7'></tfoot><noframes id='135734A5A7'>

    • <optgroup id='135734A5A7'><strike id='135734A5A7'><sup id='135734A5A7'></sup></strike><code id='135734A5A7'></code></optgroup>
        1. <b id='135734A5A7'><label id='135734A5A7'><select id='135734A5A7'><dt id='135734A5A7'><span id='135734A5A7'></span></dt></select></label></b><u id='135734A5A7'></u>
          <i id='135734A5A7'><strike id='135734A5A7'><tt id='135734A5A7'><pre id='135734A5A7'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:93972
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more
          New research casts further doubt on a common procedure used with IVF
          New research casts further doubt on a common procedure used with IVF

          AdobeAcommoninvitrofertilizationprocedureofferedtopatientswiththepromiseofincreasingtheirlikelihoodo

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Petition to FDA: Get the lead out of consumer hair dyes

          AlissaAmbrose/STATWASHINGTON—Backin1980,whentheFoodandDrugAdministrationapprovedtheuseofleadacetatei